GlaxoSmithKline GSK announced that the company has submitted a Biologics License Application (BLA) for CERVARIX(R) (human papillomavirus vaccine, AS04 adjuvant-adsorbed), its cervical cancer candidate vaccine, to the U.S. Food and Drug Administration (FDA).
The University of Texas M. D. Anderson Cancer Center has joined the U.S.-Middle East Partnership for Breast Cancer Awareness and Research, a collaboration designed to increase early breast cancer detection and reduce related deaths in the region through improved awareness, increased clinical resources and world-class research.
Novartis to launch its own branded version of a leading multiple sclerosis therapy through agreement with Bayer Schering Pharma.
The University of Rochester Medical Center (URMC) and T.I.E.S., LLC a Rochester, New York-based start-up company, have entered into a research partnership to evaluate a new technology that could ultimately represent a major advance in medical imaging.
With the help of a new type of suture based on MIT research, patients who get stitches may never need to have them removed.
The Alzheimer’s Association reports that in 2007 there are now more than 5 million people in the United States living with Alzheimer’s disease. Someone develops Alzheimer?s every 72 seconds, according to new Alzheimer?s Association report.
In a speech at the Chief Executives Club of Boston, Eli Lilly and Company (NYSE: LLY) chairman and chief executive officer, Sidney Taurel, predicted that the coming biomedical revolution will move medicine from its current state of treating symptoms to predicting and preventing diseases.
World diabetes leaders left the Global Changing Diabetes Leadership Forum, which took place in New York City on 13?14 March 2007, with a sense of activism to return home to start changing diabetes.
Insmed Inc., (NASDAQ: INSM) announced that it has restructured its operations as a result of the litigation settlement with Tercica Inc. (NASDAQ: TRCA) and Genentech Inc. (NYSE: DNA), which was announced yesterday, ending all litigation between the parties.
Avalon Pharmaceuticals, Inc. (NASDAQ and NYSE ArcaEx: AVRX) announced a drug discovery, development and commercialization collaboration with Merck & Co., Inc. to identify and develop inhibitors for an undisclosed target that is important in the development of cancer.